Home » Stocks » ELTP

Elite Pharmaceuticals, Inc. (ELTP)

Stock Price: $0.0644 USD -0.0016 (-2.42%)
Updated Oct 23, 2020 3:59 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 54.54M
Revenue (ttm) 22.17M
Net Income (ttm) -1.44M
Shares Out 846.96M
EPS (ttm) 0.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $0.0644
Previous Close $0.0660
Change ($) -0.0016
Change (%) -2.42%
Day's Open 0.0615
Day's Range 0.0612 - 0.0657
Day's Volume 285,325
52-Week Range 0.05 - 0.115

More Stats

Market Cap 54.54M
Enterprise Value 56.79M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 846.96M
Float 598.18M
EPS (basic) n/a
EPS (diluted) 0.00
FCF / Share 0.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 757,074
Short Ratio 0.87
Short % of Float 0.13%
Beta 1.00
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.46
PB Ratio 4.63
Revenue 22.17M
Operating Income -307,103
Net Income -1.44M
Free Cash Flow -1.17M
Net Cash -2.24M
Net Cash / Share 0.00
Gross Margin 35.98%
Operating Margin -1.38%
Profit Margin -6.50%
FCF Margin -5.27%
ROA -0.74%
ROE -12.11%
ROIC -16.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.00*
Low
4.00
Current: $0.0644
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue17.997.577.469.6412.505.024.603.402.424.27
Revenue Growth137.76%1.47%-22.61%-22.89%149.21%8.99%35.19%40.4%-43.18%-
Gross Profit7.982.873.953.748.012.001.371.091.411.59
Operating Income-2.29-9.16-9.05-7.36-8.32-16.51-5.28-1.56-1.97-0.89
Net Income-2.24-9.28-3.673.81-0.685.22-41.261.49-15.06-13.58
Shares Outstanding832814796839674591463349259100
Earnings Per Share--0.01-0.01-0.01-0.01-0.02-0.21--0.06-0.14
Operating Cash Flow-1.79-6.79-4.81-7.88-2.77-15.10-4.22-1.69-0.391.55
Capital Expenditures-0.03-0.02-0.27-1.10-1.95-2.00-0.50-0.15-0.62-0.49
Free Cash Flow-1.83-6.81-5.08-8.99-4.71-17.10-4.72-1.85-1.021.06
Cash & Equivalents1.132.287.1810.5911.517.857.210.640.952.12
Total Debt4.033.983.992.653.443.123.933.990.010.01
Net Cash / Debt-2.90-1.703.197.958.074.733.27-3.350.942.10
Assets24.9624.4030.8834.3131.6725.9224.3211.1310.3111.79
Liabilities14.3013.0112.418.6520.5125.6510619.8025.3029.66
Book Value10.66-2.514.5725.66-33.12-34.73-81.20-8.67-14.98-17.87
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Elite Pharmaceuticals, Inc.
Country United States
Employees 43
CEO Nasrat A. Hakim

Stock Information

Ticker Symbol ELTP
Stock Exchange US OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier OTCMKTS: ELTP
IPO Date July 23, 1998

Description

Elite Pharmaceuticals engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets for pains under the Dilaudid brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Methadone HCl tablets for pains under the Dolophine brand; and Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; and SequestOX, an immediate release Oxycodone with Naltrexone. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. It has a manufacturing and license agreement with Epic Pharma LLC; development and license agreement with SunGen Pharma, LLC; and strategic marketing alliance with Glenmark Pharmaceuticals, Inc. USA, as well as Lannett Company. Inc. The company was founded in 1984 and is headquartered in Northvale, New Jersey.